[1] 澤田徹, 種田二郎, 岡本幸市, ほか. 無症候性脳血管障害の診断基準に関する研究[J]. 脳卒中, 1997, 19(6):489-493.
[2] 藤井進也, 松末英司. ラクナ梗死と血管周囲腔[J]. 画像診断, 2005, 25:1326-1327.
[3] ROUHL RP, VAN OOSTENBRUGGE RJ, KNOTTNERUS IL, et al. Virchow-Robin spaces relate to cerebral small vessel disease severity[J]. J Neurol, 2008, 255(5):692-696.
[4] SELVARAJAH J, SCOTT M, STIVAROS S, et al. Potential surrogate markers of cerebral microvascular angiopathy in asymptomatic subjects at risk of stroke[J]. Eur Radiol, 2009, 19(4):1011-1018.
[5] ZHU YC, TZOURIO C, SOUMARé A, et al. Severity of dilated Virchow-Robin spaces is associated with age, blood pressure, and MRI markers of small vessel disease: a population-based study[J]. Stroke, 2010, 41(11):2483-2490.
[6] XU Y, WANG L, HE J, et al. Prevalence and control of diabetes in Chinese adults[J]. JAMA, 2013, 310(9):948-959.
[7] YANG Z, XING X, XIAO J, et al. Prevalence of cardiovascular disease and risk factors in the Chinese population with impaired glucose regulation: the 2007-2008 China national diabetes and metabolic disorders study[J]. Exp Clin Endocrinol Diabetes, 2013, 121(6):372-374.
[8] PINTO A, TUTTOLOMONDO A, DI RAIMONDO D, et al. A case control study between diabetic and non-diabetic subjects with ischemic stroke[J]. Int Angiol, 2007, 26(1):26-32.
[9] 曲　红, 周蔓蔓, 张玉倩, 等. MRI上血管周围间隙与血管性危险因子及脑梗死发病的相关性[J]. 中国医学影像学杂志, 2012, 20(9):641-645.
[10] WINDHAM BG, DEERE B, GRISWOLD ME, et al. Small brain lesions and incident stroke and mortality: a cohort study[J]. Ann Intern Med, 2015, 163(1):22-31.
[11] KNOPMAN DS, GRISWOLD ME, LIRETTE ST, et al. Vascular imaging abnormalities and cognition mediation by cortical volume in nondemented individuals: atherosclerosis risk in communities-neurocognitive study[J]. Stroke, 2015, 46(2):433-440.
[12] 曲　红, 张玉倩, 周蔓蔓, 等. 脑内微小病变不同干预模式的临床疗效比较[J]. 中国中西医结合杂志, 2013, 33(3):332-337.
[13] PUTAALA J, LIEBKIND R, GORDIN D, et al. Diabetes mellitus and ischemic stroke in the young: clinical features and long-term prognosis[J]. Neurology, 2011, 76(21):1831-1837.
[14] ABBOTT NJ, PATABENDIGE AA, DOLMAN DE, et al. Structure and function of the blood-brain barrier[J]. Neurobiol Dis, 2010, 37(1):13-25.
[15] TANNE D, KOREN-MORAG N, GOLDBOURT U. Fasting plasma glucose and risk of incident ischemic stroke or transient ischemic attacks: a prospective cohort study[J]. Stroke, 2004, 35(10):2351-2355.
[16] MARSO SP, KENNEDY KF, HOUSE JA, et al. The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: a systematic review and meta-analysis[J]. Diab Vasc Dis Res, 2010, 7(2):119-130.
[17] STEVENS RJ, COLEMAN RL, ADLER AI, et al. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66[J]. Diabetes Care, 2004, 27(1): 201-207.
[18] MYINT PK, SINHA S, WAREHAM NJ, et al. Glycated hemoglobin and risk of stroke in people without known diabetes in the European Prospective Investigation into Cancer (EPIC)-Norfolk prospective population study: a threshold relationship?[J]. Stroke, 2007, 38(2):271-275.
[19] AMARENCO P, LABREUCHE J, TOUBOUL PJ. High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: a systematic review[J]. Atherosclerosis, 2008, 196(2):489-496.
[20] Cholesterol Treatment Trialists’ (CTT) Collaborators, KEARNEY PM, BLACKWELL L, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomized trials of statins: a meta-analysis[J]. Lancet, 2008, 371(9607):117-125.
[21] YANG X, KO GT, SO WY, et al. Additive interaction of hyperglycemia and albuminuria on risk of ischemic stroke in type 2 diabetes: Hong Kong Diabetes Registry[J]. Diabetes Care, 2008, 31(12):2294-2300.
[22] KUWASHIRO T, KAMOUCHI M, AGO T, et al. The factors associated with a functional outcome after ischemic stroke in diabetic patients: the Fukuoka Stroke Registry[J]. J Neurol Sci, 2012, 313(1-2):110-114.
[23] URABE T, WATADA H, OKUMA Y, et al. Prevalence of abnormal glucose metabolism and insulin resistance among subtypes of ischemic stroke in Japanese patients[J]. Stroke, 2009, 40(4):1289-1295.
[24] PARDRIDGE WM. Drug transport across the blood-brain barrier[J]. J Cereb Blood Flow Metab, 2012, 32(11):1959-1972.
[25] PEDRAM MZ, SHAMLOO A, ALASTY A, et al. Optimal magnetic field for crossing super-para-magnetic nanoparticles through the brain blood barrier: a computational approach[J/OL]. Biosensors (Basel), 2016, 6(2):25(2016-06-14)[2017-10-18]. http://www.mdpi.com/2079-6374/6/2/25. DOI: 10.3390/bios6020025.
[26] ZEPEDA AB, PESSOA A JR, CASTILLO RL, et al. Cellular and molecular mechanisms in the hypoxic tissue: role of HIF-1 and ROS[J]. Cell Biochem Funct, 2013, 31(6):451-459.
[27] MALIK RA, TESFAYE S, NEWRICK PG, et al. Sural nerve pathology in diabetic patients with minimal but progressive neuropathy[J]. Diabetologia, 2005, 48(3):578-585.
[28] KRISTOVá V, LíSKOVá S, SOTNíKOVá R, et al. Sulodexide improves endothelial dysfunction in streptozotocin-induced diabetes in rats[J]. Physiol Res, 2008, 57(3):491-494.
[29] DANEMAN R. The blood-brain barrier in health and disease[J]. Ann Neurol, 2012, 72(5):648-672.
[30] BOHUSLAVOVA R, KOLAR F, SEDMERA D, et al. Partial deficiency of HIF-1α stimulates pathological cardiac changes in streptozotocin-induced diabetic mice[J/OL]. BMC Endocr Disord, 2014, 14:11(2014-02-06)[2017-10-18]. https://doi.org/10.1186/1472-6823-14-11. DOI: 10.1186/1472-6823-14-11.
[31] ORTEGA A, FERNáNDEZ A, ARENAS MI. Outcome of acute renal injury in diabetic mice with experimental endotoxemia: role of hypoxia-inducible factor-1 α[J/OL]. J Diabetes Res, 2013:254529(2013-07-31)[2017-10-18]. http://dx.doi.org/10.1155/2013/254529. DOI: 10.1155/2013/254529.
[32] NAKAGAWA K, KOHARA T, UEHATA Y, et al. PIAS3 enhances the transcriptional activity of HIF-1α by increasing its protein stability[J]. Biochem Biophys Res Commun, 2016, 469(3):470-476.
[33] NISHIYAMA Y, GODA N, KANAI M, et al. HIF-1α induction suppresses excessive lipid accumulation in alcoholic fatty liver in mice[J]. J Hepatol, 2012, 56(2):441-447.
[34] WANG V, DAVIS DA, HAQUE M, et al. Differential gene up-regulation by hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha in HEK293T celIs[J]. Cancer Res, 2005, 65(8):3299-3306.
[35] NICHOLAS SA, SUMBAYEV VV. The role of redox-dependent mechanisms in the downregulation of ligand-induced Toll-like receptors 7, 8 and 4-mediated HIF-1 alpha proly hydroxylation[J]. Immunol Cell Biol, 2010, 88(2):180-186.
[36] WEN Z, HUANG C, XU Y, et al. a-Solanine inhibits vascular endothelial growth factor expression by down-regulating the ERK1/2-HIF-1α and STAT3 signaling pathways[J]. Eur J Pharmacol, 2016, 771:93-98.
[37] NISHIJIMA K, NG YS, ZHONG L, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury[J]. Am J Pathol, 2007, 171(1):53-67.
[38] PARK CW, KIM HW, LIM JH, et al. Vascular endothelial growth factor inhibition by dRK6 causes endothelial apoptosis, fibrosis, and inflammation in the heart via the Akt/eNOS axis in db/db mice[J]. Diabetes, 2009, 58(11):2666-2676.
[39] SIOMEK A. NF-κB signaling pathway and free radical impact[J]. Acta Biochim Pol, 2012, 59(3):323-331.
[40] NAZIR FS, ALEM M, SMALL M, et al. Blunted response to systemic nitric oxide synthase inhibition in the cerebral circulation of patients with Type 2 diabetes[J]. Diabet Med, 2006, 23(4):398-402.
[41] 陈玉华, 苏健民, 武　革,等. 内皮素、降钙素基因相关肽参与糖尿病合并脑梗死发病过程中的作用[J]. 中国临床康复, 2003, 7(15):2141-2143.
[42] JOUTEL A, CORPECHOT C, DUCROS A, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia[J]. Nature, 1996, 383(6602):707-710.
[43] ANASTASI E, CAMPESE AF, BELLAVIA D, et al. Expression of activated Notch3 in transgenic mice enhances generation of T regulatory cells and protects against experimental autoimmune diabetes[J]. J Immunol, 2003, 171(9):4504-4511.
[44] BORSELLO T, CLARKE PG, HIRT L, et al. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia[J]. Nat Med, 2003, 9(9):1180-1186.
[45] KANETO H, NAKATANI Y, MIYATSUKA T, et al. Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide[J]. Nat Med, 2004, 10(10):1128-1132.
[46] 吴以岭. 络病治疗原则与通络药物[J]. 疑难病杂志, 2005, 4(4):213-215.
[47] 朱良春. 先发制病，早用通利[J]. 中国社区医师, 2003, 18(11):23-24.
[48] 姜春华. 姜春华与“截断扭转”理论[J]. 中国社区医师, 2005, 21(15):34-34.
[49] 赵锡武. 赵锡武医疗经验[M]. 北京:人民卫生出版社, 1950:47.
[50] 姜春华. 扭转截断重祛邪，先证而治勿因循[J]. 中国社区医师, 2003, 18(11):21-23.
[51] 青木茂樹. よくわかる脳MRI[M]. 東京: 株式会社秀潤社, 1998:14-16.
[52] 曲　红, 西丸雄也. 从脑内微小病变探讨中风“治未病”客观依据的研究[J]. 天津中医药, 2008, 25(4):292-295.
[53] 曲　红, 张玉倩, 赵小英, 等. 桂枝茯苓丸加地龙干预脑内微小病变及预防脑梗死发病的临床研究[J]. 上海中医药杂志, 2012, 46(8):15-21.
[54] 周小祝，莫志贤. 桂枝茯苓丸的药理作用研究进展[J]. 医药导报, 2006, 25(2):142-143.
[55] 刘笑迎, 曹　贺, 钟　萍. 益气养阴活血方治疗糖尿病周围神经病变效果观察[J]. 人民军医, 2015, 58(8):914-916.
[56] 刘笑迎, 张云云, 张捷青, 等. 黄芪、丹参、山药及其复方对高糖所致雪旺细胞凋亡的保护作用[J]. 中药药理与临床, 2010, 26(1):41-45.
[57] TOSHIMA Y, SATOH S, IKEGAKI I, et al. A new model of cerebral microthrombosis in rats and the neuroprotective effect of a Rho-kinase inhibitor[J]. Stroke, 2000, 31(9):2245-2250.